智通财经APP讯,和誉-B(02256)发布公告,公司的附属公司上海和誉生物医药科技有限公司宣布,其口服、高效、高选择性小分子KRAS G12D抑制剂ABSK141,已在针对携带KRAS G12D突变的晚期实体瘤患者的I/II期临床试验中已成功完成首例患者给药。
智通财经APP讯,和誉-B(02256)发布公告,公司的附属公司上海和誉生物医药科技有限公司宣布,其口服、高效、高选择性小分子KRAS G12D抑制剂ABSK141,已在针对携带KRAS G12D突变的晚期实体瘤患者的I/II期临床试验中已成功完成首例患者给药。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.